Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Author:
Affiliation:
1. Department of Endocrinology, Key Laboratory of Endocrinology of the National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Publisher
American Medical Association (AMA)
Subject
Internal Medicine
Link
https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2790392/jamainternal_he_2022_oi_220009_1650900276.01193.pdf
Reference43 articles.
1. Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes.;Kalyani;N Engl J Med,2021
2. GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk.;Liuzzo;Eur Heart J,2021
3. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.;Marx;Lancet Diabetes Endocrinol,2021
4. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk.;Marx;Eur Heart J,2020
5. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.;Wadden;JAMA,2021
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. GLP-1 agonists: A review for emergency clinicians;The American Journal of Emergency Medicine;2024-04
2. Glucagon-like peptide-1 receptor agonists in the perioperative period;European Journal of Anaesthesiology;2024-02-02
3. Statistical declarations versus scientific inferences and clinical judgments: the association of Glucagon-like peptide-1 receptor agonist use with the risk of biliary disease;Frontiers in Endocrinology;2024-01-29
4. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks;Alimentary Pharmacology & Therapeutics;2024-01-02
5. Glucagon-like Peptide-1 Agonists;JBJS Reviews;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3